IMA
IMA
NASDAQ · Pharmaceuticals

Imagenebio Inc

$4.12
+0.07 (+1.73%)
As of Nov 7, 2:29 AM ET ·
Financial Highlights (FY 2026)
Revenue
1.86M
Net Income
-105,299,548
Gross Margin
—
Profit Margin
-5,668.6%
Rev Growth
-62.9%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 31.5% 31.5%
Operating Margin -6,056.4% -5,450.7% 13.4% 16.1%
Profit Margin -5,668.6% -5,385.2% 10.3% 13.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 1.86M 5.00M 44.29M 39.41M
Gross Profit — — 13.97M 12.43M
Operating Income -112,474,179 -272,554,553 5.94M 6.35M
Net Income -105,299,548 -255,168,533 4.55M 5.11M
Gross Margin — — 31.5% 31.5%
Operating Margin -6,056.4% -5,450.7% 13.4% 16.1%
Profit Margin -5,668.6% -5,385.2% 10.3% 13.0%
Rev Growth -62.9% -62.9% -0.9% +2.4%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 19.74M 17.02M
Total Equity — — 39.52M 44.51M
D/E Ratio — — 0.50 0.38
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -111,575,538 -285,397,848 9.89M 9.22M
Free Cash Flow — — 3.33M 3.29M